<DOC>
	<DOC>NCT01428531</DOC>
	<brief_summary>The purpose of this post-marketing surveillance study is to collect and assess information on safety and efficacy of fondaparinux injection in patients with venous thromboembolism (VTE). ("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)</brief_summary>
	<brief_title>Special Drug Use Investigation for ArixtraÂ® (Fondaparinux) Venous Thromboembolism Treatment</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Patients with acute pulmonary thromboembolism or acute deep venous thrombosis Fondaparinux injection must be prescribed for the first time</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>